D-penicillamine in patients with rheumatoid arthritis. Serum levels, pharmacokinetic aspects, and correlation with clinical course and side effects

After administration of D-penicillamine to patients with rheumatoid arthritis, measurements of serum level and urinary excretion showed half-life times of 1.6 hours in the rapid phase and 4-6 days in the slow phase. The latter evidence suggests that tissue pooling occurs. With a dosage of 750 mg/day...

Full description

Saved in:
Bibliographic Details
Published inArthritis and rheumatism Vol. 27; no. 12; p. 1362
Main Authors Muijsers, A O, van de Stadt, R J, Henrichs, A M, Ament, H J, van der Korst, J K
Format Journal Article
LanguageEnglish
Published United States 01.12.1984
Subjects
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - metabolism
Cysteine - blood
Drug Administration Schedule
Humans
Intestinal Absorption
Kinetics
Penicillamine - administration & dosage
Penicillamine - blood
Penicillamine - pharmacology
Penicillamine - therapeutic use
Penicillamine - urine
Time Factors
Online AccessGet more information

Cover

More Information
Summary:After administration of D-penicillamine to patients with rheumatoid arthritis, measurements of serum level and urinary excretion showed half-life times of 1.6 hours in the rapid phase and 4-6 days in the slow phase. The latter evidence suggests that tissue pooling occurs. With a dosage of 750 mg/day, basic serum levels of 100 microM are gradually reached. Serum D-penicillamine levels were shown to be the same for patients who responded well to treatment, those who did not respond, and for patients who had adverse side effects as well as those who had none. Intestinal resorption decreased when D-penicillamine was taken close to meals and was greatly reduced by iron preparations.
ISSN:0004-3591
DOI:10.1002/art.1780271206